Print
PDF
Creatinine Clearance Calculator & Ideal Body Weight Calculator (powered by MDCalc)
Notations: ID-R: restricted antimicrobial (follow link for details) IV-PO: similar drug levels obtained with IV or PO administration
Dosing Weights: IBW=ideal body weight (use TBW if IBW is greater than patient's weight) ABW=adjusted body weight TBW=total body weight
Drug |
CrCl >50 mL/min |
CrCl 10-50 mL/min
|
CrCl <10 ml/min |
||
| Acyclovir IBW ID-R: VASF | |||||
| Herpes simplex infections | 5 mg/kg/dose IV q8h |
25-50 mL/min 5 mg/kg/dose IV q12h |
10-25 mL/min 5mg/kg/dose IV q24h |
2.5 mg/kg IV q24h | |
| HSV encephalitis/Herpes zoster | 10 mg/kg/dose IV q8h |
25-50 mL/min 10 mg/kg/dose IV q12h |
10-25 mL/min 10mg/kg/dose IV q24h |
5 mg/kg IV q24h | |
|
Amphotericin B Lipid Formulations *Use Total Body Weight if Total Body Weight < Ideal Body Weight. If Total Body Weight >1.2 times Ideal Body Weight, use Adjusted Body Weight IV Fluids: Give 500mL Normal Saline before and after AmBisome administration if able to tolerate |
|||||
| Invasive fungal infections | 3 - 5 mg/kg IV q24h | No adjustment for renal dysfunction | |||
| Prophylaxis (heme-onc) | 1 mg/kg IV q24h | No adjustment for renal dysfunction | |||
| Ampicillin | |||||
| Meningitis or endovascular infection | 2 g IV q4h | 2 g IV q6h | 1 g IV q8h | ||
| Uncomplicated Infection | 2 g IV q6h | 1 g IV q6h | 1 g IV q12h | ||
| Ampicillin/sulbactam |
>30 mL/min 3 g IV q6h |
15-30 mL/min 1.5 g IV q6h |
<15 mL/min 1.5 g IV q12h |
||
| Azithromycin |
Community acquired pneumonia ICU: 500mg IV/PO q24h Non-ICU: 500mg IV/PO x1 then 250mg IV/PO q24h |
No adjustment for renal dysfunction |
|||
| Aztreonam ID-R: SFGH VASF | 2 g IV q8h | 2 g IV q12h | 1 g IV q12h | ||
| Caspofungin ID-R: UCSF SFGH VASF |
Loading Dose=70 mg x1, then 50 mg IV q24h Severe hepatic dysfunction: 70 mg Loading Dose x1, then 35 mg IV q24h |
No adjustment for renal dysfunction |
|||
| Cefazolin | |||||
| Gram Negative or Complicated Gram Positive | 2 g IV q8h |
1 – 2 g IV q12h |
1 g IV q24h |
||
| Uncomplicated Gram Positive | 1 – 2 g IV q8h | ||||
| Cefepime ID-R: SFGH VASF |
> 60 mL/min 2 g IV q12h |
30-60 mL/min 2 g IV q24h |
10-29 mL/min 1 g IV q24h |
<10 mL/min 500 mg IV q24h |
|
|
Febrile neutropenia, meningitis, Pseudomonas, critically-ill |
2 g IV q8h | 2 g IV q12h | 2 g IV q24h | 1 g IV q24h | |
|
Ceftazidime |
2 g IV q8h |
31-50 mL/min 2 g IV q12 |
15-30 mL//min 2g IV q24h |
<15 mL/min 500 mg IV q24h |
|
| Ceftriaxone | |||||
| Standard Dose (e.g. Pneumonia) | 1 g IV q24h |
No adjustment for renal dysfunction |
|||
| Meningitis | 2 g IV q12h | ||||
| Endocarditis & Osteomyelitis | 2 g IV q24h | ||||
| Ciprofloxacin IV-PO ID-R: VASF |
>30 mL/min 400 mg IV q12h 500-750 mg PO q12h |
10-30 mL/min 200-400 mg IV q12h 250-500 mg PO q12h |
<10 mL/min 200 mg IV q12h 250 mg PO q12h |
||
| Pseudomonas infections |
>30 mL/min 400 mg IV q8h |
10-30 mL/min 200-400 mg IV q12h 250-500 mg PO q12h |
<10 mL/min 200 mg IV q12h 250 mg PO q12h |
||
| Clindamycin ID-R: VASF | 600 – 900 mg IV q8h | No adjustment for renal dysfunction | |||
| Colistin IBW ID-R: UCSF SFGH VASF | 5 mg/kg IV x 1 loading dose, then contact ID Pharmacy for maintenance dosing recommendations | ||||
| Daptomycin TBW ID-R: UCSF SFGH VASF Not effective in treatment of pneumonia. Round dose to nearest 250mg increment. |
6 – 10 mg/kg IV q24h Dose depends on indication & pathogen |
<30 mL/min 6 – 10 mg/kg IV Q48h |
|||
| Doxycycline IV-PO | 100 mg IV/PO q12h | No adjustment for renal dysfunction | |||
| Ertapenem |
>30 mL/mIn 1 g IV q24h |
<30 mLmin 500 mg IV q24h |
|||
| Ethambutol IBW |
15-20 mg/kg PO q24h 40-55 kg: 800 mg 56-75 kg: 1200 mg 76-90 kg: 1600 mg |
<30 mlLmin 15-25 mg/kg PO three times weekly |
|||
| Fluconazole IV-PO | |||||
| Candidiasis | 100–400 mg IV/PO q24h | 50 – 200 mg IV/PO q24h | 50 -100 mg IV/PO q24h | ||
| Oropharyngeal | 100 mg IV/PO q24h | ||||
| Esophageal | 200 mg IV/PO q24h | ||||
| Severe Infections |
<= 80kg: 400 mg IV/PO q24h 81-100kg: 600mg IV/PO q24h >100kg 800mg IV/PO q24h |
||||
| Flucytosine (5FC)IBW |
> 50 mL/min 25 mg/kg/dose PO q6h |
25-50 mL/min 25 mg/kg/dose PO q12h |
10-25 mL/min 25 mg/kg/dose |
<10 mL/min 12.5 mg/kg/dose po Q24h |
|
| Ganciclovir TBW ID-R: SFGH VASF |
> 70 mL/min 5 mg/kg/dose IV q12h |
50 - 69 mL/min 2.5 mg/kg/dose IV q12h |
25-49 mL/min 2.5 mg/kg/dose IV q24h |
10-24 mL/min 1.25 mg/kg/dose IV |
|
| Gentamicin IBW* *Use TBW if < IBW. If TBW > 1.2 times IBW, use ABW See also Aminoglycoside Dosing & Monitoring Recommendations
|
>60 mL/min 7mg/kg/dose IV Q24h |
See Below | |||
| Use once-daily dosing in patients with normal renal function, who are not morbidly obese or fluid overloaded. Check serum drug level 6-14 hours after start of infusion. Consult pharmacy or ID pharmacy for level interpretation or see Aminoglycoside Dosing & Monitoring Recommendations | |||||
| Use traditional dosing regimen for patients who do not qualify for once-daily dosing. | |||||
|
>60 mL/min 1.6 mg/kg IV q8h |
40-60 mL/min 1.2 - 1.5 mg/kg IV q12h |
20-40 mL/min 1.2 - 1.5 mg/kg IV q12-24h |
< 20 mL/min 2 mg/kg Loading Dose (Consult pharmacy for maintenance) |
||
| In traditional dosing for gram (-) infections, monitor peak (5-8 mg/L) and trough (< 2 mg/L) levels. Lower doses of 1 mg/kg q8h are used for gram (+) synergy; monitor peak (3-4 mg/L) and trough (< 1 mg/L). See also Aminoglycoside Dosing & Monitoring Recommendations |
|||||
| Isoniazid | 300 mg PO q24h | No adjustment for renal dysfunction | |||
| Levofloxacin IV-PO ID-R: VASF | |||||
| Urinary tract infections | 250-500 mg IV/PO q24h |
20-49 mL/min 500 mg x1, then 250 mg IV/PO q24h |
<20 mL/min 500 mg x1, then 250 mg IV/PO q48h |
||
| Non-urinary tract infections | 750 mg IV/PO q24h |
20-49 mL/min 750 mg IV/PO q48h |
<20 mL/min 750 mg x1, then 500 mg IV/PO q48h |
||
| Linezolid IV-PO ID-R: UCSF SFGH VASF | 600 mg IV/PO q12h | No adjustment for renal dysfunction | |||
| Meropenem ID-R: SFGH VASF |
> 50 mL/min 0.5-1 g IV q8h |
26 - 50 mL/min 0.5-1 g IV q12h |
10-25 mL/min 0.5 g IV q12h |
< 10 mL/min 0.5 g IV q24h |
|
| Meningitis, cystic fibrosis | 2 g IV q8h | 2 g IV q12h | 1 g IV q12h | 1 g IV q24h | |
| Metronidazole IV-PO | 500 mg IV/PO q8h | 500 mg IV/PO q12h | |||
| Moxifloxacin IV-PO ID-R: SFGH VASF | 400 mg IV/PO q24h | No adjustment for renal dysfunction | |||
| Nafcillin | |||||
| Meningitis, osteomyelitis or endovascular infection | 2 g IV q4h | No adjustment for renal dysfunction | |||
| Uncomplicated infection | 1-2 g IV q6h | ||||
| Penicillin G ID-R: SFGH | |||||
| Meningitis, endovascular infection | 3 - 4 MU IV q4h |
1 - 2 MU IV q4 - 6h |
1 MU IV q6h |
||
| Uncomplicated infection | 2 - 3 MU IV q4 - 6h | ||||
|
EXTENDED INFUSION Piperacillin/ tazobactam (Zosyn)ID-R: SFGH PREFERRED dosing strategy if no exclusions Full policy & procedure here |
All infections, including documented/suspected Pseudomonas infections CrCl >= 20 mL/min 4.5g IV over 30 minutes x1, then 4.5g IV over 4 hours q8h starting 4h after loading dose |
2.25 g IV q8h | |||
|
SHORT INFUSION Piperacillin/ tazobactam (Zosyn)ID-R: SFGH ONLY for patients meeting exclusions for extended infusion |
3.375 g IV q6h | 3.375 g IV q6-8h | 2.25g IV q8h | ||
| Documented/suspected Pseudomonas infections: | 4.5 g IV q6h for CrCl >20 mL/min | ||||
| Posaconazole SUSPENSION ID-R: UCSF SFGH VASF Must be administered with high-fat meal or nutritional shake i.e Ensure |
|||||
| Treatment of invasive fungal infections | 400 mg PO q12h or 200 mg PO q6h |
No adjustment for renal dysfunction |
|||
| Neutropenia/GVHD prophylaxis | 200 mg PO q8h | ||||
|
Posaconazole TABLETS Take with food |
300mg PO q12h x2 doses, then 300mg po q24h | No adjustment for renal dysfunction | |||
| Pyrazinamide IBW |
20-25 mg/kg PO q24h 40-55 kg: 1000 mg 56-75 kg: 1500 mg 76-90 kg: 2000 mg |
<30 mL/min 25-35 mg/kg po three times weekly |
|||
|
Strongly recommended review of concurrent medications due to many potential drug interactions |
|||||
| Mycobacterial infections | 600 mg IV/PO q24h |
No adjustment for renal dysfunction |
|||
| Prosthetic device infections | 300 mg PO q12h | ||||
| Endocarditis |
300 mg PO q8h Hold rifampin until negative blood cultures |
||||
| Tigecycline ID-R: UCSF SFGH VASF |
100 mg IV x 1, then 50 mg IV q12h Severe hepatic dysfunction: 100 mg IV x1, then 25 mg IV q12h |
No adjustment for renal dysfunction |
|||
| Tobramycin | See Gentamicin | ||||
| TMP/SMX IV-PO, ABW* SS Tablet: 80mg TMP DS Tablet: 160 TMP *May consider TBW for serious infections |
|||||
| Systemic GNR infections | 10 mg TMP/kg/day IV/PO divided q6-12h | 5-7.5 mg TMP/kg/day IV/PO divided q12-24h | 2.5-5 mg TMP/kg IV/PO Q24h | ||
| Pneumocystis pneumonia | 15-20 mg TMP/kg/day IV/PO divided q6-12h | 10-15 mg TMP/kg/day IV/PO divided q12-24h | 5-10 mg TMP/kg IV/PO q24h | ||
|
Valganciclovir CMV Treatment Induction Maintenance |
>= 60mL/min 900mg PO q12h 900mg PO q24h |
50-59 mL/min 450mg PO q12h 450mg PO q24h |
25-39 mL/min 450mg PO q24h 450mg PO q48h |
10-24 mL/min 450mg PO q48h 450mg PO twice weekly |
Not recommended; consider IV ganciclovir |
|
CMV Prophylaxis |
Refer to individual service protocol | ||||
|
VancomycinTBW |
|||||
|
VoriconazoleIV-PO, ABW Strongly recommended review of concurrent medications due to many potential drug interactions |
400 mg PO q12h x 2 doses, Mild-to-moderate hepatic dysfunction: Consider reduction of maintenance dosage by 50% |
No adjustment for renal dysfunction**
|
|||
|
IV dose: LD=6 mg/kg/dose q12h x 2 doses, then 4 mg/kg/dose (ABW) Q12h. *In obese patients consider a weight-based PO regimen (4 mg/kg q12h ABW), consult ID or ASP for assistance. **IV formulation should be avoided if possible in patients with CrCl<50 mL/min due to the accumulation of the IV vehicle. Monitor trough levels for treatment of serious infections, therapy failure, or signs of toxicity; obtain trough level on day 5 of therapy for a new regimen or dose change. |
|||||